Literature DB >> 28582640

The causes of thrombocytopenia after transcatheter aortic valve implantation.

Maciej Mitrosz1, Remigiusz Kazimierczyk2, Bozena Sobkowicz2, Ewa Waszkiewicz2, Pawel Kralisz3, Marek Frank1, Jaroslaw Piszcz4, Marzenna Galar4, Slawomir Dobrzycki3, Wlodzimierz J Musial2, Tomasz Hirnle1, Karol A Kaminski5, Agnieszka M Tycinska6.   

Abstract

INTRODUCTION: Even though thrombocytopenia following transcatheter aortic valve implantation (TAVI) has been described, further investigation of this phenomenon is needed. AIMS: To determine which factors may explain the fall in platelet count that occurs after implantation of a TAVI device, including markers of platelet and blood coagulation activation.
MATERIAL AND METHODS: 32 patients without previous indications for dual antiplatelet therapy (mean age 78.5±7.9 years, 62% females) with severe aortic valve stenosis (mean gradient 54.6±16.9mmHg) who qualified for TAVI procedure (Edwards Sapien XT) were prospectively analyzed. Platelet counts were analyzed before the surgery, on the day of the procedure and for the three following postoperative days (POD 1 to 3). To assess platelet activation P-selectin (PS, serum) and platelet factor 4 (PF-4, CTAD plasma) were measured, whereas for the evaluation of coagulation activation prothrombin fragments 1+2 (F1+2, plasma) were assessed before the procedure, on POD-1 and POD-3 (ELISA).
RESULTS: During the postoperative period a significant platelet count drop, the most evident on POD-2, was observed followed by a platelet count raise. The platelet count drop correlated directly with the amount of iodinated contrast agent (r=0.42, p=0.016) and inversely with baseline mean platelet volume (r=-0.37, p=0.046). Neither clinical nor perioperative parameters, except contrast medium, influenced platelet count decrease. No significant differences regarding the concentration of the evaluated markers in patients with and without thrombocytopenia were found. PF-4 and F1+2 significantly changed during the study (p<0.05). Greater acute PF-4 decrease correlated with greater acute platelet count drop (r=0.48, p=0.043), and during the study slower PF-4 increase correlated with higher platelet count increase on POD-3 (r=-0.505, p=0.032). Lower baseline PS correlated with lower baseline platelet count and higher platelet count increase on POD-3 (r=0.45, p=0.04 and =-0.55, p=0.02, respectively). No significant correlations between F1+2 concentrations and platelet count changes have been found.
CONCLUSIONS: Platelet reduction shortly after TAVI procedure is related to the amount of contrast agent applied during the procedure. Platelet activation and blood coagulation along with impaired baseline platelet renewal might be the mechanisms of thrombocytopenia following TAVI procedure.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Coagulation activation; Mechanisms of thrombocytopenia; Platelet activation; TAVI

Mesh:

Year:  2017        PMID: 28582640     DOI: 10.1016/j.thromres.2017.05.020

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation - The ATTRACTIVE-TTAS study.

Authors:  Masanobu Ishii; Koichi Kaikita; Tatsuro Mitsuse; Nobuhiro Nakanishi; Yu Oimatsu; Takayoshi Yamashita; Suguru Nagamatsu; Noriaki Tabata; Koichiro Fujisue; Daisuke Sueta; Seiji Takashio; Yuichiro Arima; Kenji Sakamoto; Eiichiro Yamamoto; Kenichi Tsujita
Journal:  Int J Cardiol Heart Vasc       Date:  2019-03-28

Review 2.  Quantitative and Qualitative Platelet Derangements in Cardiac Surgery and Extracorporeal Life Support.

Authors:  Enrico Squiccimarro; Federica Jiritano; Giuseppe Filiberto Serraino; Hugo Ten Cate; Domenico Paparella; Roberto Lorusso
Journal:  J Clin Med       Date:  2021-02-06       Impact factor: 4.241

3.  Association between time-related changes in routine blood morphological parameters and renal function after transcatheter aortic valve implantation - a preliminary study.

Authors:  Konrad Stelmark; Eli Adrian Zaher; Anna Olasińska-Wiśniewska; Michael Adesina; Alicia Dragone; Martha Isaac; Marcin Misterski; Marek Grygier; Mateusz Puślecki; Maciej Lesiak; Marek Jemielity; Bartłomiej Perek
Journal:  Kardiochir Torakochirurgia Pol       Date:  2021-10-05

4.  Can Blood Biomarkers Help Predicting Outcome in Transcatheter Aortic Valve Implantation?

Authors:  Cécile Oury; Alain Nchimi; Patrizio Lancellotti; Jutta Bergler-Klein
Journal:  Front Cardiovasc Med       Date:  2018-03-28

5.  Thrombocytopenia After Transcatheter Valve-in-Valve Implantation: Prognostic Marker or Mere Finding?

Authors:  Renato C de Souza; Leonardo Paim; Guilherme Viotto; Joaquim Aprigio; Lucas L Araújo; Henrique Ribeiro; Roney O Sampaio; Flavio Tarasoutchi; Pablo M A Pomerantzeff; José Honório Palma; Fabio B Jatene
Journal:  Braz J Cardiovasc Surg       Date:  2018 Jul-Aug

6.  Predictors of short-term thrombocytopenia after transcatheter aortic valve implantation: a retrospective study at a single Japanese center.

Authors:  Yasutaka Yamada; Daisuke Miura; Ayako Takamori; Eijiro Nogami; Junji Yunoki; Yoshiro Sakaguchi
Journal:  BMC Res Notes       Date:  2020-11-16

7.  Thrombocytopenia Complicating Transcatheter Aortic Valve Implantation: Differences Between Two New-Generation Devices.

Authors:  Nicola Corcione; Simona Romano; Alberto Morello; Paolo Ferraro; Michele Cimmino; Michele Albanese; Martina Tufano; Daniela Capasso; Salvatore Buonpane; Salvatore Giordano; Martino Pepe; Giuseppe Biondi-Zoccai; Maria Fiammetta Romano; Arturo Giordano
Journal:  J Cardiovasc Transl Res       Date:  2021-03-15       Impact factor: 4.132

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.